Base de dados : MEDLINE
Pesquisa : D02.092.471.683.943 [Categoria DeCS]
Referências encontradas : 410 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 41 ir para página                         

  1 / 410 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:29342497
[Au] Autor:El-Sayeh HG; Rathbone J; Soares-Weiser K; Bergman H
[Ad] Endereço:Harrogate District Hospital, Tees, Esk & Wear Valleys NHS Foundation Trust, Briary Wing, Lancaster Park Road, Harrogate, North Yorkshire, UK, HG2 7SX.
[Ti] Título:Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia.
[So] Source:Cochrane Database Syst Rev;1:CD000458, 2018 01 18.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Tardive dyskinesia (TD) is a disabling movement disorder associated with the prolonged use of antipsychotic medication. Several strategies have been examined in the treatment of TD. Currently, however, there is no clear evidence of the effectiveness of these drugs in TD and they have been associated with many side effects. One particular strategy would be to use pharmaceutical agents which are known to influence the catecholaminergic system at various junctures. OBJECTIVES: 1. To determine the effects of any of the following drugs for antipsychotic-induced TD in people with schizophrenia or other chronic mental illnesses.i. Drugs which influence the noradrenergic system.ii. Dopamine receptor agonists.iii. Dopamine receptor antagonists.iv. Dopamine-depletor drugs.v. Drugs that increase the production or release of dopamine.2. To examine whether any improvement occurred with short periods of intervention (less than 6 weeks) and, if this did occur, whether this effect was maintained at longer periods of follow-up.3. To examine if there was a differential effect for the various compounds.4. To examine whether the use of non-antipsychotic catecholaminergic drugs are most effective in those with more recent onset TD (less than five years). SEARCH METHODS: We retrieved 712 references from searching the Cochrane Schizophrenia Group Trials Register (July 2015 and April 2017). We also inspected references of all identified studies for further trials and contacted authors of trials for additional information. SELECTION CRITERIA: We selected studies if they were randomised controlled trials focusing on people with schizophrenia or other chronic mental illnesses and antipsychotic-induced tardive dyskinesia. We compared the use of catecholaminergic interventions versus placebo, no intervention, or any other intervention for the treatment of antipsychotic-induced tardive dyskinesia. DATA COLLECTION AND ANALYSIS: We independently extracted data from these trials and we estimated risk ratios (RRs) with 95% confidence intervals (CIs). We assumed that people who left the studies early had no improvement. MAIN RESULTS: There are 10 included trials (N = 261) published between 1973 and 2010; eight are new from the 2015 and 2017 update searches. Forty-eight studies are excluded. Participants were mostly chronically mentally ill inpatients in their 50s, and studies were primarily of short (2 to 6 weeks) duration. The overall risk of bias in these studies was unclear, mainly due to poor reporting of allocation concealment and generation of the sequence. Studies were also not clearly blinded and we are unsure if data are incomplete or selectively reported, or if other biases were operating.One small, three-arm trial found that both alpha-methyldopa (N = 20; RR 0.33, 95% CI 0.14 to 0.80; low-quality evidence) and reserpine (N = 20; RR 0.52 95% CI 0.29 to 0.96; low-quality evidence) may lead to a clinically important improvement in tardive dyskinesia symptoms compared with placebo after 2 weeks' treatment, but found no evidence of a difference between alpha-methyldopa and reserpine (N = 20; RR 0.60, 95% CI 0.19 to 1.86; very low quality evidence). Another small trial compared tetrabenazine and haloperidol after 18 weeks' treatment and found no evidence of a difference on clinically important improvement in tardive dyskinesia symptoms (N = 13; RR 0.93, 95% CI 0.45 to 1.95; very low quality evidence). No study reported on adverse events.For remaining outcomes there was no evidence of a difference between any of the interventions: alpha-methyldopa versus placebo for deterioration of tardive dyskinesia symptoms (1 RCT; N = 20; RR 0.33, 95% CI 0.02 to 7.32; very low quality evidence), celiprolol versus placebo for leaving the study early (1 RCT; N = 35; RR 5.28, 95% CI 0.27 to 102.58; very low quality evidence) and quality of life (1 RCT; N = 35; RR 0.87, 95% CI 0.68 to 1.12; very low quality evidence), alpha-methyldopa versus reserpine for deterioration of tardive dyskinesia symptoms (1 RCT; N = 20; not estimable, no reported events; very low quality evidence), reserpine or carbidopa/levodopa versus placebo for deterioration of tardive dyskinesia symptoms (2 RCTs; N = 37; RR 1.18, 95% CI 0.35 to 3.99; very low quality evidence), oxypertine versus placebo for deterioration of mental state (1 RCT; N = 42; RR 2.20, 95% CI 0.22 to 22.45; very low quality evidence), dopaminergic drugs (amantadine, bromocriptine, tiapride, oxypertine, carbidopa/levodopa) versus placebo for leaving the study early (6 RCTs; N = 163; RR 1.29, 95% CI 0.65 to 2.54; very low quality evidence), and tetrabenazine versus haloperidol for deterioration of tardive dyskinesia symptoms (1 RCT; N = 13; RR 1.17, 95% CI 0.09 to 14.92) and leaving the study early (1 RCT; N = 13; RR 0.23, 95% CI 0.01 to 4.00). AUTHORS' CONCLUSIONS: Although there has been a large amount of research in this area, many studies were excluded due to inherent problems in the nature of their cross-over designs. Usually data are not reported before the cross-over and the nature of TD and its likely response to treatments make it imprudent to use this data. The review provides little usable information for service users or providers and more well-designed and well-reported studies are indicated.
[Mh] Termos MeSH primário: Antidiscinéticos/uso terapêutico
Antipsicóticos/efeitos adversos
Discinesia Induzida por Medicamentos/tratamento farmacológico
[Mh] Termos MeSH secundário: Inibidores da Captação Adrenérgica/uso terapêutico
Celiprolol/uso terapêutico
Progressão da Doença
Antagonistas de Dopamina/uso terapêutico
Haloperidol/uso terapêutico
Seres Humanos
Metildopa/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto
Reserpina/uso terapêutico
Tetrabenazina/uso terapêutico
Cloridrato de Tiapamil/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Adrenergic Uptake Inhibitors); 0 (Anti-Dyskinesia Agents); 0 (Antipsychotic Agents); 0 (Dopamine Antagonists); 56LH93261Y (Methyldopa); 8B1QWR724A (Reserpine); DRB57K47QC (Celiprolol); J6292F8L3D (Haloperidol); V824N2T753 (Tiapamil Hydrochloride); Z9O08YRN8O (Tetrabenazine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180118
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD000458.pub3


  2 / 410 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22085742
[Au] Autor:Mediavilla C; Mahía J; Bernal A; Puerto A
[Ad] Endereço:Psychobiology, University of Granada, Campus Cartuja, 18071 Granada, Spain. cristina@ugr.es
[Ti] Título:The D2/D3-receptor antagonist tiapride impairs concurrent but not sequential taste aversion learning.
[So] Source:Brain Res Bull;87(2-3):346-9, 2012 Feb 10.
[Is] ISSN:1873-2747
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Taste aversion learning (TAL) is a learning modality in which the animals reject a gustatory stimulus associated with the administration of noxious visceral substances. This learning can be established by concurrent or sequential procedures that involve different anatomical and functional mechanisms and may constitute distinct learning modalities. The dopaminergic system has been related to various learning processes and goal-directed behaviours. The present study examined the effect of the administration of tiapride, a D(2)/D(3) dopaminergic antagonist, on concurrent and sequential TAL. Results obtained showed that pre-treatment with tiapride blocks the acquisition of concurrent TAL but does not affect sequential TAL, including reversal learning tasks. These results demonstrate the involvement of the D(2)/D(3) dopaminergic receptors in the former but not the latter learning process. The dopaminergic system appears to participate in concurrent TAL, an "implicit" learning modality, but not in sequential TAL, which is considered a relational/explicit acquisition process.
[Mh] Termos MeSH primário: Aprendizagem da Esquiva/efeitos dos fármacos
Discriminação (Psicologia)/efeitos dos fármacos
Antagonistas de Dopamina/toxicidade
Transtornos de Aprendizagem/induzido quimicamente
Paladar/efeitos dos fármacos
Cloridrato de Tiapamil/toxicidade
[Mh] Termos MeSH secundário: Análise de Variância
Animais
Modelos Animais de Doenças
Esquema de Medicação
Masculino
Ratos
Ratos Wistar
Aprendizagem Seriada/efeitos dos fármacos
Fatores de Tempo
Privação de Água/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Dopamine Antagonists); V824N2T753 (Tiapamil Hydrochloride)
[Em] Mês de entrada:1208
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:111117
[St] Status:MEDLINE
[do] DOI:10.1016/j.brainresbull.2011.10.022


  3 / 410 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22100559
[Au] Autor:Nobilis M; Vybíralová Z; Szotáková B; Sládková K; Kunes M; Svoboda Z
[Ad] Endereço:Institute of Experimental Biopharmaceutics, Joint Research Center of PROMEDCS Praha as and Academy of Sciences of the Czech Republic, Hradec Králové, Czech Republic. nobilis@uebf.cas.cz
[Ti] Título:High-performance liquid chromatographic determination of tiapride and its phase I metabolite in blood plasma using tandem UV photodiode-array and fluorescence detection.
[So] Source:J Chromatogr B Analyt Technol Biomed Life Sci;879(32):3845-52, 2011 Dec 15.
[Is] ISSN:1873-376X
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:New bioanalytical SPE-HPLC-PDA-FL method for the determination of the neuroleptic drug tiapride and its N-desethyl metabolite was developed, validated and applied to xenobiochemical and pharmacokinetic studies in humans and animals. The sample preparation process involved solid-phase extraction of diluted plasma spiked with sulpiride (an internal standard) using SPE cartridges DSC-PH Supelco, USA. Chromatographic separation of the extracts was performed on a Discovery HS F5 250 mm × 4 mm (Supelco) column containing pentafluorophenylpropylsilyl silica gel. Mobile phase (acetonitrile-0.01 M phosphate buffer pH=3, flow rate 1 ml min(-1)) in the gradient mode was employed in the HPLC analysis. Tandem UV photodiode-array→fluorescence detection was used for the determination of the analytes. Low concentrations of tiapride and N-desethyl tiapride were determined using a more selective fluorescence detector (λ(exc.)/λ(emiss.)=232 nm/334 nm), high concentrations (500-6000 pmol ml(-1)) using a UV PDA detector at 212 nm with a linear response. Each HPLC run lasted 15 min. Lower limits of quantification (LLOQ) for tiapride (N-desethyl tiapride) were found to be 8.24 pmol ml(-1) (10.11 pmol ml(-1)). The recoveries of tiapride ranged from 89.3 to 94.3%, 81.7 to 86.8% for internal standard sulpiride and 90.9 to 91.8% for N-desethyl tiapride.
[Mh] Termos MeSH primário: Cromatografia Líquida de Alta Pressão/métodos
Espectrometria de Fluorescência/métodos
Espectrofotometria Ultravioleta/métodos
Cloridrato de Tiapamil/análogos & derivados
Cloridrato de Tiapamil/sangue
[Mh] Termos MeSH secundário: Animais
Seres Humanos
Limite de Detecção
Modelos Lineares
Masculino
Microssomos Hepáticos/metabolismo
Ratos
Reprodutibilidade dos Testes
Extração em Fase Sólida
Sulpirida/sangue
Cloridrato de Tiapamil/farmacocinética
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
7MNE9M8287 (Sulpiride); V824N2T753 (Tiapamil Hydrochloride)
[Em] Mês de entrada:1203
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:111122
[St] Status:MEDLINE
[do] DOI:10.1016/j.jchromb.2011.10.032


  4 / 410 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:22093417
[Au] Autor:Liu ZS; Chen YH; Zhong YQ; Zou LP; Wang H; Sun D; Wang DB; Liao JX
[Ad] Endereço:Department of Neurology, Wuhan Children's Hospital, Wuhan 430016, China.
[Ti] Título:[A multicenter controlled study on aripiprazole treatment for children with Tourette syndrome in China].
[So] Source:Zhonghua Er Ke Za Zhi;49(8):572-6, 2011 Aug.
[Is] ISSN:0578-1310
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:OBJECTIVE: To evaluate the efficacy and safety of aripiprazole in the treatment of children with Tourette syndrome. METHOD: A prospective, multi-center, controlled clinical trial was conducted in 195 children aged 5-17 years with Tourette syndrome. The patients were assigned to two groups: aripiprazole group (n=98) and tiapride group (n=97), with the treatment dosage of 5-25 mg/d and 100-500 mg/d, respectively. After 12 weeks treatment, the clinical efficacy was assessed by the Yale Global Tic Severity Scale (YGTSS) score, and adverse reactions were observed by side effects symptoms scale, blood biochemical indexes, and electrocardiography. RESULT: Significant pre- and post-treatment differences were ascertained for motor tic, phonic tic, function damage and total scores of YGTSS in the both groups from the second week of treatment (P<0.0001). Compared with the tiapride group, the aripiprazole group showed a more significantly decreased function damage score of YGTSS by the second week of treatment (P<0.05). After 12 weeks treatment, total scores of YGTSS in the aripiprazole group decreased from 53.74±15.71 at baseline to 24.36±16.38, while in the tiapride group from 51.66±13.63 to 23.26±15.31. The mean reduction scores of YGTSS were 29.38 in the aripiprazole group and 28.40 in the tiapride group at the end of treatment, and the clinical response rates were 60.21% and 63.92%, respectively. There were no significant differences between the 2 groups (P>0.05). The incidence of adverse reactions was similar in the aripiprazole and tiapride groups, with 29.6% and 27.8% respectively. There were no significant differences in the incidence of adverse reactions between aripiprazole and tiapride groups and no severe adverse events were found in either group. CONCLUSION: The results showed that aripiprazole showed similar therapeutic effect to tiapride in treatment of children with Tourette syndrome. Aripiprazole was safe and well tolerated in Chinese population, and can be considered as a new valid option for the treatment of tic disorders.
[Mh] Termos MeSH primário: Antipsicóticos/uso terapêutico
Piperazinas/uso terapêutico
Quinolonas/uso terapêutico
Síndrome de Tourette/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Aripiprazol
Criança
Pré-Escolar
Feminino
Seres Humanos
Masculino
Estudos Prospectivos
Cloridrato de Tiapamil/uso terapêutico
Resultado do Tratamento
[Pt] Tipo de publicação:CONTROLLED CLINICAL TRIAL; ENGLISH ABSTRACT; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (Piperazines); 0 (Quinolones); 82VFR53I78 (Aripiprazole); V824N2T753 (Tiapamil Hydrochloride)
[Em] Mês de entrada:1204
[Cu] Atualização por classe:160607
[Lr] Data última revisão:
160607
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:111119
[St] Status:MEDLINE


  5 / 410 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:21769061
[Au] Autor:Müller CA; Schäfer M; Banas R; Heimann HM; Volkmar K; Förg A; Heinz A; Hein J
[Ad] Endereço:Department of Psychiatry, Universitätsmedizin Berlin, Berlin, Germany. ch.mueller@charite.de
[Ti] Título:A combination of levetiracetam and tiapride for outpatient alcohol detoxification: a case series.
[So] Source:J Addict Med;5(2):153-6, 2011 Jun.
[Is] ISSN:1932-0620
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Optimal pharmacotherapy of the alcohol withdrawal syndrome (AWS) in outpatient settings is still a matter of discussion. The aim of this evaluation was to examine the efficacy and tolerability of a combination of levetiracetam and tiapride for outpatient alcohol detoxification. METHODS: This was an open-label evaluation. After screening eligibility for outpatient detoxification, 9 alcohol-dependent patients received levetiracetam and tiapride in a flexible dosage regimen up to 2500 and 300 mg/d, respectively, for a maximum of 7 days. Severity of alcohol withdrawal was assessed daily using the Alcohol Withdrawal Syndrome Scale (AWSS). RESULTS: All patients completed the treatment successfully. The mean initial doses of levetiracetam and tiapride were 2166.7 and 300 mg/d, respectively. AWS as indicated by the AWSS score decreased clearly over 5 days. The combination of levetiracetam and tiapride was well tolerated. Neither treatment discontinuations because of side effects of the medication nor serious medical complications were observed during the detoxification. CONCLUSIONS: The results of this evaluation provide first evidence that the combination of levetiracetam and tiapride might be an effective and safe treatment option for mild to moderate AWS in outpatient settings. Further randomized controlled trials are warranted to confirm these preliminary results.
[Mh] Termos MeSH primário: Alcoolismo/reabilitação
Antagonistas de Dopamina/uso terapêutico
Nootrópicos/uso terapêutico
Piracetam/análogos & derivados
Síndrome de Abstinência a Substâncias/tratamento farmacológico
Cloridrato de Tiapamil/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Quimioterapia Combinada
Feminino
Seres Humanos
Masculino
Meia-Idade
Pacientes Ambulatoriais
Piracetam/uso terapêutico
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dopamine Antagonists); 0 (Nootropic Agents); 230447L0GL (etiracetam); V824N2T753 (Tiapamil Hydrochloride); ZH516LNZ10 (Piracetam)
[Em] Mês de entrada:1108
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110720
[St] Status:MEDLINE
[do] DOI:10.1097/ADM.0b013e3181ec5f81


  6 / 410 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:21558662
[Au] Autor:Zayed SI
[Ad] Endereço:Faculty of Industrial Education, Beni Suef University, Egypt. sayed_imai@yahoo.com
[Ti] Título:Differential pulse anodic voltammetric determination of tiapride hydrochloride in pharmaceutical preparation and human urine using carbon paste electrodes.
[So] Source:Anal Sci;27(5):535, 2011.
[Is] ISSN:1348-2246
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:The anodic voltammetric behavior of tiapride hydrochloride (TiapCl) was studied at carbon paste electrodes in 0.04 M Britton-Robinson buffer pH 7.0 using cyclic and differential pulse voltammetric techniques. The oxidation of TiapCl is an irreversible diffusion-controlled process. A differential pulse anodic voltammetric procedure has been developed for determination of the drug over the concentration range 0.36 - 19.35 µg/ml with detection and quantification limits of 0.12 and 0.40 µg/ml, respectively. The proposed method was successfully applied for the determination of the drug in commercial tablets and in spiked human urine samples.
[Mh] Termos MeSH primário: Carbono/química
Preparações Farmacêuticas/química
Cloridrato de Tiapamil/análise
[Mh] Termos MeSH secundário: Eletroquímica
Eletrodos
Seres Humanos
Oxirredução
Valores de Referência
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Pharmaceutical Preparations); 7440-44-0 (Carbon); V824N2T753 (Tiapamil Hydrochloride)
[Em] Mês de entrada:1110
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110512
[St] Status:MEDLINE


  7 / 410 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:20658244
[Au] Autor:Kovacs N; Herold R; Janszky J; Komoly S; Nagy F
[Ti] Título:Tics status: a movement disorder emergency: observations.
[So] Source:J Neurol;258(1):143-5, 2011 Jan.
[Is] ISSN:1432-1459
[Cp] País de publicação:Germany
[La] Idioma:eng
[Mh] Termos MeSH primário: Transtornos dos Movimentos/etiologia
Tiques/etiologia
Síndrome de Tourette/complicações
[Mh] Termos MeSH secundário: Adolescente
Antipsicóticos/efeitos adversos
Clonazepam/efeitos adversos
Creatina Quinase/metabolismo
Manual Diagnóstico e Estatístico de Transtornos Mentais
Serviços Médicos de Emergência
Moduladores GABAérgicos/efeitos adversos
Haloperidol/efeitos adversos
Seres Humanos
Masculino
Transtornos dos Movimentos/diagnóstico
Transtornos dos Movimentos/terapia
Síndrome de Abstinência a Substâncias/fisiopatologia
Cloridrato de Tiapamil/efeitos adversos
Tiques/diagnóstico
Tiques/terapia
Síndrome de Tourette/terapia
[Pt] Tipo de publicação:CASE REPORTS; LETTER; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (GABA Modulators); 5PE9FDE8GB (Clonazepam); EC 2.7.3.2 (Creatine Kinase); J6292F8L3D (Haloperidol); V824N2T753 (Tiapamil Hydrochloride)
[Em] Mês de entrada:1104
[Cu] Atualização por classe:170928
[Lr] Data última revisão:
170928
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:100727
[St] Status:MEDLINE
[do] DOI:10.1007/s00415-010-5680-7


  8 / 410 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:20656570
[Au] Autor:Phapale PB; Lee HW; Lim MS; Seong SJ; Kim EH; Park J; Lee M; Hwang SK; Yoon YR
[Ad] Endereço:Department of Molecular Medicine, Kyungpook National University School of Medicine, Daegu, South Korea.
[Ti] Título:Liquid chromatography-tandem mass spectrometry quantification of levosulpiride in human plasma and its application to bioequivalence study.
[So] Source:J Chromatogr B Analyt Technol Biomed Life Sci;878(24):2280-5, 2010 Aug 15.
[Is] ISSN:1873-376X
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:An improved method for determining levels of levosulpiride in human plasma using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was developed and validated. The protein precipitation method was used for plasma sample preparation. Levosulpiride and an internal standard (IS) were isocratically separated on a UPLC BEH C(18) column with a mobile phase of ammonium formate buffer (1mM, adjusted to pH 3 with formic acid) and acetonitrile (60:40, v/v). MS/MS detection was performed by monitoring the parent-->daughter pair of levosulpiride and the IS at m/z 342-->112 and 329-->256, respectively. The method was linear from 2.5 to 200ng/mL and exhibited acceptable precision and percent recovery. The method was successfully demonstrated in pharmacokinetic and bioequivalence studies of two levosulpiride oral formulations administered to healthy volunteers. When compared to the previous LC-MS methods, the proposed method is faster, well-validated, and uses lesser plasma volume and a similar sensitivity. The use of UPLC allowed rapid and sensitive quantification of levosulpiride, making this method suitable for high-throughput clinical applications.
[Mh] Termos MeSH primário: Cromatografia Líquida de Alta Pressão/métodos
Sulpirida/análogos & derivados
Espectrometria de Massas em Tandem/métodos
[Mh] Termos MeSH secundário: Adulto
Seres Humanos
Masculino
Reprodutibilidade dos Testes
Sensibilidade e Especificidade
Sulpirida/sangue
Sulpirida/farmacocinética
Equivalência Terapêutica
Cloridrato de Tiapamil/análise
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
7MNE9M8287 (Sulpiride); JTG7R315LK (levosulpiride); V824N2T753 (Tiapamil Hydrochloride)
[Em] Mês de entrada:1011
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:100727
[St] Status:MEDLINE
[do] DOI:10.1016/j.jchromb.2010.06.036


  9 / 410 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:20540847
[Au] Autor:Liu YY; Chen YH; Chen H; Liu ZS
[Ad] Endereço:Department of Pediatrics, Affiliated Union Hospital, Fujian Medical University, Fuzhou 350001, China.
[Ti] Título:[A control study of aripiprazole and tiapride treatment for tic disorders in children].
[So] Source:Zhongguo Dang Dai Er Ke Za Zhi;12(6):421-4, 2010 Jun.
[Is] ISSN:1008-8830
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:OBJECTIVE: To evaluate the efficacy and safety of aripiprazole in the treatment of tic disorder when tiapride is used as a control. METHODS: Sixty-five children aged 6-14 years old with tic disorders were randomly assigned to two groups: aripiprazole (2.5-10 mg/d) and tiapride treatment (25- 400 mg/d). After 12 weeks treatment, the clinical efficacy was assessed by the Yale Global Tie Severity Scale (YGTSS) score and the adverse reactions were observed. RESULTS: The YGTSS score in both groups decreased from the second week of treatment. Compared with the tiapride treatment group, the aripirazole treatment group showed a more decreased YGTSS score (29+/-13)% vs (16+/-14)%; P<0.01 by the second week of treatment. The overall effective rate in the aripiprazole and tiapride treatment groups was 91% and 84%, respectively (P>0.05) 12 weeks after treatment. There were no significant differences in the incidence of adverse reactions between the aripiprazole and tiapride treatment groups and no severe adverse events were found in either group. CONCLUSIONS: Low dose aripiprazole is safe and effective for treatment of tic disorders in children, suggesting that it represents a new valid option for the treatment of tic disorder.
[Mh] Termos MeSH primário: Antipsicóticos/uso terapêutico
Piperazinas/uso terapêutico
Quinolonas/uso terapêutico
Cloridrato de Tiapamil/uso terapêutico
Transtornos de Tique/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Aripiprazol
Criança
Feminino
Seres Humanos
Masculino
Piperazinas/efeitos adversos
Quinolonas/efeitos adversos
Cloridrato de Tiapamil/efeitos adversos
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (Piperazines); 0 (Quinolones); 82VFR53I78 (Aripiprazole); V824N2T753 (Tiapamil Hydrochloride)
[Em] Mês de entrada:1009
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:100615
[St] Status:MEDLINE


  10 / 410 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:20078487
[Au] Autor:Martinotti G; di Nicola M; Frustaci A; Romanelli R; Tedeschi D; Guglielmo R; Guerriero L; Bruschi A; De Filippis R; Pozzi G; Di Giannantonio M; Bria P; Janiri L
[Ad] Endereço:Clinica Villa Maria Pia, Via del Forte Trionfale 36, Rome 00135 Italy. giovanni.martinotti@libero.it
[Ti] Título:Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi-centre, randomized, single-blind comparison trial.
[So] Source:Addiction;105(2):288-99, 2010 Feb.
[Is] ISSN:1360-0443
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The aim of this trial was to compare lorazepam with non-benzodiazepine medications such as pregabalin and tiapride in the treatment of alcohol withdrawal syndrome (AWS). These drugs were chosen for their inhibitorial effects on the hypersecretion of neurotransmitters usually observed in AWS. Craving reduction and improvement of psychiatric symptoms were the secondary end-points. METHODS: One hundred and ninety subjects affected by current alcohol dependence were considered consecutively: 111 were enrolled and divided into three groups of 37 subjects each. Within a treatment duration of 14 days, medication was given up to the following maximum doses (pregabalin 450 mg/day; tiapride 800 mg/day; lorazepam 10 mg/day). Withdrawal (CIWA-Ar), craving [visual analogue scale (VAS); Obsessive and Compulsive Drinking Scale (OCDS)], psychiatric symptoms [Symptom Check List 90 Revised (SCL-90-R)] and quality of life (QL-index) rating scales were applied. RESULTS: On the CIWA-Ar score, all the groups showed a significant reduction between times (P < 0.001) with a higher reduction for the pregabalin group (P < 0.01) on items regarding headache and orientation. Retention in treatment was lower in the tiapride group (P < 0.05), while the number of subjects remaining alcohol free was higher in the pregabalin group (P < 0.05). Significant reduction between baseline and the end of the treatment was found in all the groups at the OCDS and the VAS for craving, at the SCL-90-R and QL-index (P < 0.001). DISCUSSION: All the medications in the trial showed evidence of safety and efficacy in the treatment of uncomplicated forms of AWS, with some particular differences. The efficacy of pregabalin was superior to that of tiapride, used largely in research trials and, for some measures, to that of the 'gold standard', lorazepam. Accordingly, pregabalin may be considered as a potentially useful new drug for treatment of AWS, deserving further investigation.
[Mh] Termos MeSH primário: Alcoolismo/tratamento farmacológico
Analgésicos/uso terapêutico
Lorazepam/uso terapêutico
Síndrome de Abstinência a Substâncias/tratamento farmacológico
Cloridrato de Tiapamil/uso terapêutico
Ácido gama-Aminobutírico/análogos & derivados
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Alcoolismo/psicologia
Alcoolismo/reabilitação
Feminino
Seres Humanos
Masculino
Meia-Idade
Pregabalina
Método Simples-Cego
Síndrome de Abstinência a Substâncias/psicologia
Resultado do Tratamento
Adulto Jovem
Ácido gama-Aminobutírico/uso terapêutico
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Analgesics); 55JG375S6M (Pregabalin); 56-12-2 (gamma-Aminobutyric Acid); O26FZP769L (Lorazepam); V824N2T753 (Tiapamil Hydrochloride)
[Em] Mês de entrada:1006
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:100119
[St] Status:MEDLINE
[do] DOI:10.1111/j.1360-0443.2009.02792.x



página 1 de 41 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde